CG Oncology’s (CGON) “Buy” Rating Reaffirmed at HC Wainwright

CG Oncology (NASDAQ:CGON)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research report issued to clients and investors on Tuesday,Benzinga reports. They presently have a $75.00 price target on the stock. HC Wainwright’s price objective would indicate a potential upside of 88.96% from the company’s current price.

CGON has been the subject of several other research reports. UBS Group assumed coverage on shares of CG Oncology in a research report on Thursday, October 24th. They set a “buy” rating and a $60.00 price objective for the company. Roth Capital raised shares of CG Oncology to a “strong-buy” rating in a research report on Tuesday, August 27th. Royal Bank of Canada started coverage on shares of CG Oncology in a research report on Monday, September 23rd. They issued an “outperform” rating and a $66.00 target price for the company. Roth Mkm started coverage on shares of CG Oncology in a research note on Tuesday, August 27th. They issued a “buy” rating and a $65.00 price objective for the company. Finally, Bank of America restated a “buy” rating and issued a $65.00 price target on shares of CG Oncology in a research report on Tuesday, October 8th. Eight analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, CG Oncology currently has a consensus rating of “Buy” and a consensus target price of $63.88.

CG Oncology Price Performance

Shares of NASDAQ:CGON opened at $39.69 on Tuesday. CG Oncology has a 1-year low of $25.77 and a 1-year high of $50.23. The company’s fifty day moving average is $36.84 and its two-hundred day moving average is $34.82.

Insider Activity

In other CG Oncology news, Director Hong Fang Song sold 650,455 shares of the company’s stock in a transaction on Thursday, August 29th. The stock was sold at an average price of $35.36, for a total value of $23,000,088.80. Following the transaction, the director now directly owns 586,982 shares of the company’s stock, valued at $20,755,683.52. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Institutional Trading of CG Oncology

Several institutional investors and hedge funds have recently modified their holdings of CGON. Decheng Capital LLC bought a new position in CG Oncology in the first quarter valued at about $239,642,000. Vanguard Group Inc. bought a new stake in CG Oncology during the 1st quarter worth approximately $97,678,000. BVF Inc. IL bought a new position in shares of CG Oncology during the first quarter valued at $82,716,000. Yu Fan bought a new stake in shares of CG Oncology in the second quarter worth $49,828,000. Finally, Janus Henderson Group PLC bought a new position in CG Oncology during the 1st quarter worth $66,757,000. 26.56% of the stock is currently owned by institutional investors.

About CG Oncology

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.